Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALG-1001 in Wet AMD
NCT01749891Phase 2Completed
- Sponsor
- Allegro Ophthalmics, LLC
- Start
- Mar 2012
- Primary completion
- Jun 2013
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of risuteganib in exudative macular degeneration, sponsored by Allegro Ophthalmics, LLC. Started Mar 2012; status: completed.
02
Drugs
risuteganib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT01749891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01749891.